Extended Clinical Benefit Over Multiple Clinical Endpoints Reported from Ph 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at longer Follow-up May 21, 2026
Updated Interim Results Announced From Ph 2 LEGEND trial of detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC patients with CIS with or without concomitant papillary disease May 21, 2026
ZUSDURI Median DOR Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial May 21, 2026
Ph 3 VIKTORIA-2 Trial of Gedatolisib in 1L HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients May 21, 2026
Perioperative Imfinzi plus neoadjuvant EV showed statistically significant EFS/OS improvements in MIBC in Ph 3 VOLGA trial May 21, 2026
Positive Updated 12-Month Data Demonstrated Durable Responses in BCG-Naïve Cohort of Ph 2 ADVANCED-2 Trial of TARA-002 in NMIBC May 21, 2026
94.5% Six-Month Duration of Response reported from Ph 3 UTOPIA Trial of UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC May 21, 2026
Re-induction with ADSTILADRIN resulted in complete responses in 31% of initial non-responders with BCG-unresponsive NMIBC May 21, 2026
FAILED TRIAL: Ph 3 Trial of Fianlimab Combination in 1L Unresectable or Metastatic Melanoma did not reach statistical significance for PFS improvement May 21, 2026
TroFuse-005 Trial of Sacituzumab Tirumotecan (Sac-TMT) Met OS/PFS Primary Endpoints in Certain Patients With Advanced or Recurrent Endometrial Cancer May 21, 2026
Part 1 Data From Ph 2 Trial of JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer Announced May 21, 2026
Positive 12-Month Follow-Up Data from Ph 2b CLOVER WaM Study Shows Durable Responses & Efficacy of Iopofosine I 131 in R/R Waldenström Macroglobulinemia May 12, 2026
Evorpacept + Zanidatamab combo Generates Durable Response in Patients with Advanced HER2+ve Breast Cancer and High CD47 Expression May 12, 2026
Interim Results Announced of US Alpha DaRT® REGAIN Trial, with 100% Local Disease Control, 67% CRR, and Favorable Safety Profile May 12, 2026
Updated Interim Results Announced From LEGEND Cohort of detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC patients with CIS with or without concomitant papillary disease May 12, 2026
50% ORR Announced in Recurrent Ovarian Cancer Ph 2 Trial of Ampligen, Pembrolizumab and Cisplatin May 12, 2026
Updated Positive Survival Observations from Ph 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy Reported May 12, 2026
Interim Ph 2 Data for INBRX-106 in 1L HNSCC Demonstrates Potential Costimulatory Benefit Over PD-1 Monotherapy May 12, 2026
Tovecimig Demonstrates Statistically Significant PFS Benefit but misses the OS benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer May 6, 2026
Ph 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful PFS Improvement in PIK3CA Mutant Cohort May 6, 2026
Journal of Clinical Oncology Publishes Final Results of Duvelisib PRIMO Ph 2 Trial in R/R Peripheral T-cell Lymphoma May 6, 2026
Positive Ph 2a Data with Namodenoson in Pancreatic Cancer Reported; 35% of Patients Remain on Therapy, Including One Beyond 16 Months May 6, 2026
